Related Experiment Video
Updated: Dec 27, 2025
Legionella pneumophila Outer Membrane Vesicles: Isolation and Analysis of Their Pro-inflammatory Potential on Macrophages
Published on: February 22, 2017
In Vitro and Intracellular Activities of Omadacycline against Legionella pneumophila
Jacques Dubois1, Maïtée Dubois2, Jean-François Martel2
1M360 Inc., Sherbrooke, Québec, Canada jdubois@m360.ca.
Abstract:
Omadacycline is an aminomethylcycline antibiotic with in vitro activity against pathogens causing community-acquired bacterial pneumonia (CABP). This study investigated the activity of omadacycline against Legionella pneumophila strains isolated between 1995 and 2014 from nosocomial or community-acquired respiratory infections. Omadacycline exhibited extracellular activity similar to comparator antibiotics; intracellular penetrance was found by day 3 of omadacycline exposure. These results support the utility of omadacycline as an effective antibiotic for the treatment of CABP caused by L. pneumophila.
Insights
Omadacycline shows effectiveness against Legionella pneumophila, a cause of pneumonia. This antibiotic penetrates bacterial cells, supporting its use for community-acquired bacterial pneumonia (CABP).
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Community-acquired bacterial pneumonia (CABP) is a significant global health concern.
- Legionella pneumophila is an important pathogen causing both nosocomial and community-acquired respiratory infections.
- Aminomethylcycline antibiotics, including omadacycline, offer potential therapeutic options for bacterial infections.
Purpose of the Study:
- To evaluate the in vitro and intracellular activity of omadacycline against clinical isolates of Legionella pneumophila.
- To compare the efficacy of omadacycline with existing antibiotics against L. pneumophila.
- To assess the potential of omadacycline for treating CABP caused by L. pneumophila.
Main Methods:
- In vitro susceptibility testing of omadacycline against L. pneumophila strains.
- Intracellular activity assays to determine omadacycline's penetration and efficacy within host cells.
- Comparative analysis with standard antibiotics used for pneumonia treatment.
Main Results:
- Omadacycline demonstrated comparable extracellular activity to comparator antibiotics against L. pneumophila.
- Significant intracellular penetration of omadacycline into host cells was observed by day 3 of exposure.
- These findings highlight omadacycline's potential to target intracellular L. pneumophila infections.
Conclusions:
- Omadacycline exhibits promising activity against Legionella pneumophila, including intracellular efficacy.
- The drug's ability to penetrate host cells supports its potential as a treatment for L. pneumophila-induced CABP.
- Further clinical investigation is warranted to confirm omadacycline's role in managing CABP.
